<?xml version="1.0" encoding="UTF-8"?>
<p id="para0041">In addition, the dimethylamino Michael adduct of 
 <bold>13</bold> known as dimethylaminomicheliolide is a pro-drug of this sesquiterpene lactone approved for clinical trials for glioblastoma treatment (
 <xref rid="bib0049" ref-type="bibr">Guo et al., 2019</xref>). This compound protects the kidneys against proteinuria, renal failure, histopathological injury, and inflammation by suppressing activation of the NF-κB signaling pathway in db/db mice (
 <xref rid="bib0080" ref-type="bibr">Liu et al., 2019</xref>). These results showed that dimethylaminomicheliolide intervention mitigated diabetic kidney disease in db/db mice without directly affecting hyperglycemia.
</p>
